ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
22 announcements with these filters
AstraZeneca Pharma India Limited received an order from the ROC, Bengaluru, imposing a total penalty of ₹0.03 Crore for a delayed filing. The company is evaluating next steps.
AstraZeneca Pharma disclosed a ₹1.88 lakh penalty from the Registrar of Companies due to a delay in filing Form MR-2.
AstraZeneca Pharma India's Dr. Sandeep Arora resigned as Director, Medical Affairs, effective September 15, 2026. The company is seeking a suitable replacement for the position.
AstraZeneca Pharma India reported receiving an ESG rating of 64 from Crisil ESG Ratings. The assessment was independently prepared using publicly available information.
The Delhi High Court has stayed the NPPA's demand notice regarding Betaloc-50 overcharging allegations until February 2027, subject to a 15% deposit of the total demand amount.
AstraZeneca Pharma India has been assigned an ESG rating of 57 by Crisil ESG Ratings based on publicly available information.
AstraZeneca Pharma India Limited appointed Mr. Arun Krishna as a Non-Executive Director effective August 17, 2026. Additionally, Ms. Bhavana Agrawal transitioned to a Non-Executive Director role.
AstraZeneca reported 30% revenue growth to ₹682.8 Crore in Q1 FY2026-27, driven by strong performance across its core Oncology and Biopharmaceutical therapy areas.
AstraZeneca Pharma India held its 47th Annual General Meeting on August 10, 2026, where shareholders approved financial statements, dividend declaration, and key director and auditor appointments.
AstraZeneca Pharma India Ltd reported revenue from operations of ₹682.8 Cr (+29.7% YoY) and net profit of ₹37.9 Cr (-32.1% YoY) for Q1 FY27.
AstraZeneca Pharma received CDSCO permission to market 'Enhertu' for an additional breast cancer indication in India. This expands the drug's therapeutic usage under regulatory approval.
AstraZeneca Pharma India Ltd scheduled a board meeting for August 10, 2026. The meeting will consider and approve unaudited financial results for the June quarter.
AstraZeneca Pharma received a Rs. 148.66 Crore demand notice from the NPPA for alleged overcharging. The company is currently evaluating the notice and potential legal actions.
AstraZeneca Pharma received a demand notice from the NPPA for Rs. 0.80 Crore regarding alleged overcharging under the Drugs (Prices Control) Order, 2013.
AstraZeneca Pharma India Limited received CDSCO approval to import and market Enhertu for an additional breast cancer indication. This regulatory milestone enables the treatment's use for HER2-positive adult patients.
Ms. Bhavana Agrawal has resigned as CFO of AstraZeneca Pharma India Ltd. Her resignation is effective August 31, 2026, to take a regional role.
AstraZeneca Pharma India Ltd filed its quarterly shareholding pattern for the period ended June 30, 2026, as required under SEBI regulations.
AstraZeneca Pharma India Limited has fixed July 31, 2026, as the record date for determining shareholder entitlement for the final dividend for financial year 2025-26.
AstraZeneca Pharma India Limited has filed its Business Responsibility and Sustainability Report for the financial year 2025-26 as per SEBI regulations.
AstraZeneca Pharma India Limited released its Annual Report for the fiscal year ended March 31, 2026. The 47th Annual General Meeting is scheduled for August 10, 2026.
AstraZeneca Pharma India will hold its 47th Annual General Meeting on August 10, 2026, via video conferencing to transact ordinary and special business.
AstraZeneca Pharma India received CDSCO approval to market Benralizumab (Fasenra) for treating Hypereosinophilic Syndrome. This regulatory clearance expands the drug's therapeutic indications in the Indian market.